Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

Affiliations

¹ Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands. Electronic address: a.dingemans@mumc.nl.
² Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands.

Comment

A-Mc Dingemans et al. Lancet Respir Med. 2019 Apr.

. 2019 Apr;7(4):291-292.

doi: 10.1016/S2213-2600(19)30043-8. Epub 2019 Mar 12.

¹ Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands. Electronic address: a.dingemans@mumc.nl.
² Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands.

No abstract available

Comment on

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. Leighl NB, et al. Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12. Lancet Respir Med. 2019. PMID: 30876831 Clinical Trial.